Market:

Emerging cellular therapies have shown incredible potential as “living drugs” that achieve personalized treatments in a variety of healthcare fields and represent a growing market of $1.8 billion with a 10% CAGR. Interviews with over 235 clinicians, researchers, and industry experts identified cell purification, transfection/ transduction, and QC/Release as key focus areas for cellular therapies. Ferrologix is developing single use cartridge based platforms in each of these application areas.

Technology:

Ferrologix’ core technology, known as “ratcheting cytometry,” employs an array of inexpensive magnetic micropillars patterned onto a plastic substrate to form a single use cartridge. When subjected to a rotating magnetic field cells which have been labeled with a magnetic antibody can be precisely manipulated in a massively parallelized format. Various chip designs can execute a variety of functions such as rapid cell purification, quantitative separation based on surface expression, and cell co-localization with transduction/transfection reagents.

Advantages:

• Quick: 10X faster than current magnetic purification platforms
• Quantitative: Separate specific cell subtypes
• Closed: Aseptic operation to meet GMP standards
• Continuous: Compatible with large volumes and cell quantities

Development Stage:

• Prototype

Patents Pending:

• PCT Application: WO2016100234A1

Select Publications:

• Micromagnetic Ratcheting Manipulation for Bioengineering Research | UCLA Dissertation
• Quantitative Magnetic Separation of Particles and Cells Using Gradient Magnetic Ratcheting | Small
• Flexible and Stretchable Micromagnet Arrays for Tunable Biointerfacing | Adv Mater. Journal

Contact:

Email: Coleman Murray, cmurray@ferrologix.com
Phone: 760-533-2826
Website: www.ferrologix.com

Graduated in 2018

Back to Top